← Back

Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.

Price · split & dividend adjusted
News & notes moving AGY.LSE
Energy Transition & Power Demand

Cordiant Digital lifts Hudson Interxchange capacity to 80% with two new deals

Cordiant Digital Infrastructure has secured two new customer agreements at its Hudson Interxchange data centre in New York, lifting contracted capacity to around 80% of the floor's saleable space. Billing on the first contract starts in September, with full deployment expected by year-end. Separately, Helium One Global's Colorado joint venture completed its first helium sale under a short-term offtake agreement after its second commercial helium trailer delivery, shifting focus to recurring sales and cash flow. Active Energy Group is expanding its UAE strategy beyond AI data centres into water, energy and critical infrastructure, noting that growing AI facilities need secure water supplies for cooling. Gaming Realms reported a 9% rise in core content licensing revenue in the first half despite a sharp increase in UK gambling tax, and has now entered 33 regulated markets including Alberta on its first day of legalised online gaming. Frontier IP Group portfolio company Pulsiv appointed Delta Matrix as its first manufacturing partner for products using its energy-efficient OSMIUM power conversion technology, targeting a market of around 600 million USB-enabled socket installations per year. Allergy Therapeutics appointed former HSBC banker Helge Weiner-Trapness as executive chairman as it explores a dual primary listing in Hong Kong.
Proactive Investors·29dRead more ▾